Relief Therapeuticsは、EB治療薬RLF-TD011の有望な予備結果を報告し、有害な細菌を減らし、創傷治癒を改善します。 Relief Therapeutics reports promising preliminary results for EB treatment RLF-TD011, reducing harmful bacteria and improving wound healing.
レイフ・セラピュティクス・ホールディング・SAは,珍しい遺伝性皮膚疾患である表皮溶解ブルロザ (EB) を標的としたRLF- TD011の臨床試験から有望な予備的な結果を報告した. Relief Therapeutics Holding SA has reported promising preliminary results from a clinical trial of RLF-TD011, targeting epidermolysis bullosa (EB), a rare genetic skin disorder. 治療により,EBの傷で有害な細菌である黄金白菌 (Staphylococcus aureus) が著しく減少し,有益な細菌が増殖し,傷の治癒が改善された. The treatment showed significant reductions in Staphylococcus aureus, a harmful bacteria in EB wounds, while enhancing beneficial bacteria and improving wound healing. FDAはRLF-TD011の孤児薬の指定を承認し,同社は追加の市場独占指定を追求する予定です. The FDA has granted RLF-TD011 orphan drug designation, and the company plans to pursue additional market exclusivity designations.